AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05300035
Drug: Recombinant human monoclonal antibody (bNAbs)
RxNorm normalized name: Anti-VEGF Humanized Monoclonal Antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1. Initiation of combination ART (1 integrase inhibitor + 2 nucleoside analogue reverse transcriptase inhibitors) with additional dual intravenous infusions of bNAbs (3BNC117LS \& 10-1074LS) between Day 7 and Day 10.~2. Analytical treatment interruption (ATI), 52 weeks later, if good immunologic and virologic conditions.~3. During ATI, plasma HIV-1 RNA and CD4 monitoring, for a maximum of 48 weeks.~4. ART resumption, if participant encounters at least one ART resumption criteria.
Trial: NCT04772079
Drug: Deucravacitinib
RxNorm normalized name: Deucravacitinib
DrugBank: Deucravacitinib (DB16650)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT05015192
Drug: NH102
RxNorm normalized name: Naloxone Hydrochloride
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablets, orally
Trial: NCT04961593
Drug: Caspofungin
RxNorm normalized name: Caspofungin
DrugBank: Caspofungin (DB00520)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For children 3 months of age, the recommended dose is 70 mg/m2 for load and then 50 mg/m2 for maintenance, intravenous injection, once daily up to 5 days.
Trial: NCT04975945
Drug: Ceftriaxone Sodium
RxNorm normalized name: Ceftriaxone Sodium
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous vs local action
Trial: NCT05766748
Drug: Azeliragon
RxNorm normalized name: Azeliragon
DrugBank: Azeliragon (DB12689)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azeliragon is an orally administered inhibitor of Receptor for Advanced Glycation Endproducts (RAGE) which is formulated as a 5mg hard gelatin capsule.
Trial: NCT05025865
Drug: Sodium Hyaluronate
RxNorm normalized name: sodium hyaluronate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium Hyaluronate of molecular weight 35 kDa will be given in capsule form to the study participants.
Trial: NCT04484740
Drug: Gepotidacin
RxNorm normalized name: gepotidacin
DrugBank: Gepotidacin (DB12134)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 1500 mg gepotidacin
Trial: NCT06647862
Drug: IMM01
RxNorm normalized name: IMM01
DrugBank: Timdarpacept (DB17544)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT06647862
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: subcutaneous injection
Trial: NCT04890093
Drug: PEN-866
RxNorm normalized name: PEN-866
DrugBank: PEN-866 (DB16186)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEN-866 will be given as an IV infusion once every week for the first two consecutive weeks out of every three-week (21 day) cycle.
Trial: NCT04890093
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vincristine will be given at a dose of 1.5 mg/m2 by IV on days 1 and 8 of each 21-day cycle
Trial: NCT04890093
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: temozolomide will be given at a dose of 100 mg/m2, orally on days 1-5, of each 21-day cycle
Trial: NCT04674826
Drug: Tralokinumab administered as 1 × X mL with Device A
DrugBank: Tralokinumab (DB12169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration
Trial: NCT03911739
Drug: Buprenorphine Injection
RxNorm normalized name: buprenorphine Injection
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly and monthly formulations of injectable, extended-release buprenorphine (BUP-XR).
Trial: NCT03911739
Drug: Buprenorphine Sublingual Product
RxNorm normalized name: buprenorphine Sublingual Product
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sublingual buprenorphine (BUP-SL), administered daily.
Trial: NCT05061550
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive Durvalumab via intravenous route.
Trial: NCT05061550
Drug: Oleclumab
RxNorm normalized name: Oleclumab
DrugBank: Oleclumab (DB15088)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Oleclumab via intravenous route.
Trial: NCT05061550
Drug: Monalizumab
RxNorm normalized name: Monalizumab
DrugBank: Monalizumab (DB12824)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Monalizumab via intravenous route.
Trial: NCT05061550
Drug: Dato-DXd
RxNorm normalized name: Datopotamab deruxtecan
DrugBank: Datopotamab deruxtecan (DB16410)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive datopotamab deruxtecan (Dato-DXd) via intravenous route.
Trial: NCT05061550
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin as chemotherapy
Trial: NCT05061550
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin as chemotherapy
Trial: NCT05061550
Drug: Pemetrexed/Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pemetrexed/Cisplatin as chemotherapy
Trial: NCT05061550
Drug: Pemetrexed/Carboplatin
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pemetrexed/Carboplatin as chemotherapy
Trial: NCT05061550
Drug: Carboplatin/Paclitaxel
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin/Paclitaxel, as chemotherapy
Trial: NCT05061550
Drug: Volrustomig
RxNorm normalized name: Volrustomig
DrugBank: Volrustomig (DB18893)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Volrustomig via intravenous route.
Trial: NCT05061550
Drug: Rilvegostomig
RxNorm normalized name: Rilvegostomig
DrugBank: Rilvegostomig (DB18991)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Rilvegostomig via intravenous route.
Trial: NCT05801133
Drug: Pirfenidone
RxNorm normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200 mg TID in the first week, 300 mg TID in the second week, and maintenance treatment of 400 mg TID from the third week until 3 months
Trial: NCT04791553
Drug: Cenobamate
RxNorm normalized name: Cenobamate
DrugBank: Cenobamate (DB06119)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cenobamate (YKP3089) is a small molecule approved in the United States (US) for the treatment of partial onset seizures (POS) in adult patients.
Trial: NCT05684484
Drug: Roflumilast 500 MCG Oral Tablet [DALIRESP]
RxNorm normalized name: Roflumilast 500 MCG Oral Tablet [DALIRESP]
DrugBank: Roflumilast (DB01656)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Roflumilast has been approved by U.S. Food and Drug Administration (FDA) for attenuating bronchial and dermatological disorders
Trial: NCT05684484
Drug: amino salicylic acid
RxNorm normalized name: para-amino salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: conventional treatment
Trial: NCT04931667
Drug: Lorecivivint
RxNorm normalized name: Lorecivivint
DrugBank: Lorecivivint (DB14883)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthcare professional-administered intra-articular (IA) injection into one or both knees as clinically indicated. Bilateral injections of 0.07 mg of LOR are allowed. IA injection performed on Day 1. Additional IA injections of LOR to same knee (with at least a 6 month separation) between Day 1 and Month 33.
Trial: NCT05662241
Drug: Obexelimab
RxNorm normalized name: Obexelimab
DrugBank: Obexelimab (DB15032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obexelimab is a monoclonal antibody that simultaneously binds CD19 and FcγRIIb, resulting in down regulation of B cell activity.
Trial: NCT06534502
Drug: Zonisamide Oral Product
RxNorm normalized name: zonisamide Oral Product
DrugBank: Zonisamide (DB00909)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Zonisamide oral suspension
Trial: NCT05198050
Drug: Letrozole tablets
RxNorm normalized name: Letrozole Tablets
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole is a third-generation non-steroidal aromatase inhibitor
Trial: NCT05198050
Drug: Misoprostol Tabets
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a synthetic prostaglandin medication
Trial: NCT04865770
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Semaglutide given subcutaneously (sc, under the skin) once weekly. Dose gradually increased over 8 weeks from 0.25 to 1.0 mg. The study will last for about 1 year.
Trial: NCT05342493
Drug: Fremanezumab 225 Mg/1.5 mL Subcutaneous Solution
DrugBank: Fremanezumab (DB14041)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The usual adult dose is 225 mg of fremanezumab (genetical recombination) administered subcutaneously as a single dose once every 4 weeks or 675 mg administered subcutaneously as a single dose once every 12 weeks.
Trial: NCT06084663
Drug: Apremilast 30 mg Tablets
RxNorm normalized name: Apremilast
DrugBank: Apremilast (DB05676)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Each film-coated tablet contains 30 mg of apremilast
Trial: NCT06084663
Drug: Otezla 30 mg film-coated tablets
RxNorm normalized name: apremilast
DrugBank: Apremilast (DB05676)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Each film-coated tablet contains 30 mg of apremilast
Trial: NCT04922424
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will ingest placebo or ingest 20 mg atorvastatin for 30 days first. We will include 30 days of washout between treatments to minimize any potential carryover effects.
Trial: NCT00078182
Drug: Tenofovir DF
RxNorm normalized name: LAMIVUDINE 300MG/TENOFOVIR DF 300MG TAB
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT06085378
Drug: Urinary Kallidinogenase for injection
RxNorm normalized name: kallidinogenase
DrugBank: Kallidinogenase (DB13197)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The 0.15 peptide nucleic acids(PNA) unit of Eurecrine for injection was dissolved in 100ml sodium chloride injection by intravenous infusion for not less than 50 minutes, once a day. The solvent can be increased and/or slowed down according to the patient's condition for 10 consecutive days, while receiving clinical routine treatment for 10 days
Trial: NCT04824352
Drug: apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib: 500 mg QD po (BSA ≥ 1.0) or 250 mg QD po (BSA \< 1.0); IE: ifosfamide 1.8 g/m2/d d1-3; etoposide 100 mg/m2/d d1-3 Q2w
Trial: NCT06222749
Drug: Intranasal oxytocin administration
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24 international units (IU) of Syntocinon, nasal spray solution; 1 ml nasal spray contains 40 I.U. oxytocin (equivalent to 67 mcg). One spray hub (0.1 ml) contains 4 I.U. oxytocin (equivalent to 6.7 mcg).
Trial: NCT06015659
Drug: Gemzar
RxNorm normalized name: Gemzar
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Nucleoside metabolic inhibitor, per standard care via intravenous infusion.
Trial: NCT05909397
Drug: ARV-471 (PF-07850327)
RxNorm normalized name: Arv-110 (protac)
DrugBank: Bavdegalutamide (DB19032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Tablets. Route of Administration: Oral
Trial: NCT05909397
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Capsules. Route of Administration: Orally
Trial: NCT05764733
Drug: Bisphosphonate
RxNorm normalized name: Bisphosphonate
DrugBank: [{(5-Chloro-2-Pyridinyl)Amino} Methylene]-1,1-Bisphosphonate (DB03649)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medicine used to treat bone problems, called osteopenia or osteoporosis.
Trial: NCT00001025
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00001025
Drug: Didanosine
RxNorm normalized name: Didanosine
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06437496
Drug: 68Ga-AAZTA-093
RxNorm normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-AAZTA-093. Tracer doses of 68Ga-AAZTA-093 will be used to image lesions of prostate cancer by PET/CT.
Trial: NCT05816655
Drug: Fulvestrant plus AI plus ribociclib
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant + AI + ribociclib +/- GnRH agonist
Trial: NCT05816655
Drug: AI plus ribociclib
DrugBank: Ribociclib (DB11730)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: AI + ribociclib +/- GnRH agonist
Trial: NCT06046053
Drug: Placebo Vaginal Film with Square Corners
DrugBank: Corn (DB10572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 2 placebo vaginal film with square corners
Trial: NCT06046053
Drug: Placebo Vaginal Film with Rounded Corners
DrugBank: Corn (DB10572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 2 placebo vaginal film with rounded corners
Trial: NCT04378244
Drug: DeltaRex-G
RxNorm normalized name: DeltaRex-G
DrugBank: Rexin G (DB16450)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an open label, dose-seeking phase 1/2 study using escalating doses of DeltaRex-G given intravenously for 7 days in a hospital setting.~The study will employ the standard Cohort of Three design (Storer, 1989). Three patients are treated at each dose level with expansion to six patients per cohort if DLT is observed in one of the three initially-enrolled patients at each dose level. If no DLT occurs in 3 patients, escalation to the next dose level will be permitted. The maximum tolerated dose is defined as the highest safely tolerated dose, where not more than one patient experienced DLT, with the next higher dose level having at least two patients who experienced DLT. No intra-patient dose escalation will take place. Patients who do not complete the 7-day treatment will be replaced.
Trial: NCT05851443
Drug: povorcitinib
RxNorm normalized name: Povorcitinib
DrugBank: Povorcitinib (DB18855)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: povorcitinib
Trial: NCT05169554
Drug: Investigational [RCA4]: standard (RC) plus amoxicillin/clavulanate (A) for 4 weeks.
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On the posology, dosage for rifampicin and clarithromycin will be standardized according to patient body weight following WHO guidelines. In general, for a 60 kg adult dosage will be RIF, 10 mg/kg once daily and CLA, 7.5 mg/kg twice daily.~Dosages for amoxicillin/clavulanate are calculated according to manufacturer indications:~Dose of amoxicillin/clavulanate 1000/125 mg twice daily, which makes a total of 2000/250 mg/day, for patients over 40 kg, and 22.5/5.6 mg/kg twice daily, which makes a total of 45/11.25 mg/kg/day, for those equal and below 40 kg. For children, posology will be adapted to the age of the patient according to drug manufacturer indications. Frequency of AMX/CLV administration will match that of CLA, twice daily.
Trial: NCT06192277
Drug: Low dose Penicillin
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low risk participants are given a low-dose of oral penicillin followed by 60 minutes of observation
Trial: NCT06555068
Drug: HRS-6209 in Combination with Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: HRS-6209 in Combination with Fulvestrant
Trial: NCT06555068
Drug: HRS-6209 in Combination with HRS-1358
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: HRS-6209 in Combination with HRS-1358
Trial: NCT04929626
Drug: Magnesium Sulfate 500 mg/ml+ ventolin
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of magnesium sulphate i.e; 250mg(0.5ml), 500mg(1ml), 750mg(1.5ml) will be used in nebulized form
Trial: NCT04929626
Drug: Ventolin
RxNorm normalized name: Ventolin
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: it will be given to control group in nebulized form after every 20 min in 1st hour
Trial: NCT01872546
Drug: HUMIRA 40mg
RxNorm normalized name: HUMIRA 40mg/0.8mL Pre-Filled Pen
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT06555068
Drug: HRS-6209 in Combination with Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HRS-6209 in Combination with Letrozole
Trial: NCT06555068
Drug: HRS-6209 in Combination with HRS-8080
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: HRS-6209 in Combination with HRS-8080
Trial: NCT04784715
Drug: Trastuzumab deruxtecan
RxNorm normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered by intravenous infusion
Trial: NCT04784715
Drug: Pertuzumab
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered by intravenous infusion
Trial: NCT04784715
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered by intravenous infusion
Trial: NCT05933863
Drug: PD-(L)1 antibody immunotherapy
RxNorm normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The treatment regimen involved in this study follows guidelines for the first-line treatment of extensive stage SCLC: cisplatin+etoposide or carboplatin+etoposide and PD-(L)1 inhibitor.
Trial: NCT05705388
Drug: Liraglutide injection
RxNorm normalized name: Liraglutide Injection
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Liraglutide is a GLP-1 agonists approved for the management of obesity. In the study, it will be Initiated at 0.6 mg subcutaneously daily for 1 week; increase by 0.6 mg/day in weekly intervals until a dose of 3 mg/day achieved. If patients do not tolerate an increased dose during dose escalation, dose escalation will be delayed for an additional week. The patient will continue at the maximal tolerated does up to 3mg per day. If the patient has not lost at least 4% of baseline body weight at 16 weeks from medication initiation, the medication will be discontinued.
Trial: NCT05386108
Drug: Elacestrant
RxNorm normalized name: Elacestrant
DrugBank: Elacestrant (DB06374)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg, 400 mg
Trial: NCT05386108
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100 mg, 150 mg
Trial: NCT05311085
Drug: Cytisine
RxNorm normalized name: Cytisine
DrugBank: Cytisine (DB09028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dosing of:~* days 1-3: one tablet (1.5mg) every two hours through the waking day (six tablets/day)~* days 4-12: one tablet every 2.5 hours (five tablets/day). Quit smoking date is day five.~* days 13-16: one tablet every three hours (four tablets/day)~* days 17-20: one tablet every 4-5 hours (three tablets/day)~* days 21-25: one tablet every six hours (two tablets/day)~Followed by a maintenance dose of cystine from day 26 to week 12 (one tablet every six hours: two tablets/day)
Trial: NCT05311085
Drug: Nicotine delivered via an e-cigarette
RxNorm normalized name: Aldex AN
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pod device delivering nicotine. Nicotine strength: 30mg/ml (3%). Flavour: Tobacco
Trial: NCT05948579
Drug: Intervention B Vilazodone Hydrochloride (HCl)
RxNorm normalized name: Vilazodone Hydrochloride
DrugBank: Vilazodone (DB06684)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vilazodone HCl will be administered at 10 mg once daily for 7 days, followed by 20 mg for 7 days, followed by 40 mg for the remainder of the trial. There must be a minimum of 7 days between dosage increases. One reduction in dose due to tolerability will be allowed. After Week 8, dose reduction for tolerability is allowed, but dose increase is not allowed.
Trial: NCT06311942
Drug: HAIC plus PD-1 inhibitors plus lenvatinib
RxNorm normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients in the triple adjuvant therapy group received one cycle of HAIC about a month after liver resection, HAIC was adopted the FOFOLX6 program (Folinic acid+5-fluorouracil+Oxaliplatin). The first cycle of PD-1 monoclonal antibody was administrated 2-4 weeks postoperatively, 200 mg IV, every 21 days for a total of 9 cycles. Lenvatinib was initiated orally 2-4 weeks postoperatively for 6 months.
Trial: NCT06311942
Drug: PD-1 inhibitors plus lenvatinib
RxNorm normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The first cycle of PD-1 monoclonal antibody was administrated 2-4 weeks postoperatively, 200 mg IV, every 21 days for a total of 9 cycles. Lenvatinib was initiated orally 2-4 weeks postoperatively for 6 months.
Trial: NCT06387329
Drug: Nitrofurantoin 100 MG
RxNorm normalized name: nitrofurantoin 100 MG
DrugBank: Nitrofurantoin (DB00698)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No additional information
Trial: NCT05265806
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each subject will be assigned to administration of oxytocin intranasal spray (24 IU).